Exclusive Patent Rights. In each case to the extent owned and controlled by Harvard: (a) the patents and patent applications listed in Exhibit 1.8 with respect to [***] (including any PCT and/or U.S. utility application claiming priority to such application(s) that are filed on or before the one year conversion date of such application(s)); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent application... identified in (a); (c) any patents issuing on any patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any patents and patent applications identified in (a) through (e).View More
Exclusive Patent Rights. In Shall mean, in each case to the extent owned and controlled by Harvard: Licensors: (a) the patents and patent applications listed in Exhibit 1.8 with respect to [***] (including any PCT and/or U.S. utility application claiming priority to such application(s) that are filed on or before the one year conversion date of such application(s)); ******; (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or... extension of any the patent application identified in (a); (c) any patents issuing on any of the patent application applications identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; thereof, and foreign equivalents of the foregoing; (d) any claim of a continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent of the patents or patent application applications identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions extensions, restorations and exclusivity periods and the like of any patents and patent applications identified in (a) through (e). View More
